No Data
No Data
Zhaojin International: China Meheco Group's industry is expected to "outperform the market" Focus on the health insurance opportunities of innovative varieties.
The new round of domestic health insurance negotiations is about to be implemented, although there is certain pressure on health insurance funds, the bank believes that the policy trend of health insurance funds supporting innovative drugs will not change.
Express News | Innovent Announces Phase 2 Clinical Study of Picankibart (Ibi112) in Chinese Patients With Ulcerative Colitis Met Primary Endpoint
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients With Ulcerative Colitis Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and
The tenth batch of national procurement reporting documents have been leaked, industry insiders: does not represent the final list of centralized procurement varieties. The competition intensity will reach new heights.
①A document of the tenth batch of national procurement reporting catalog has circulated within the industry. Today, when the reporter verified with the relevant department, they indicated that it is an internal document not for public release, and the formal joint procurement document will be released publicly later. ②Several industry experts have provided feedback to the reporter, stating that this reporting catalog does not represent the final procurement catalog. However, the competitive landscape of the tenth batch of national procurement will involve at least seven companies. ③The competition for the tenth batch of national procurement will be exceptionally fierce.
Innovent Bio (01801.HK) received JPMorgan's shareholding of 10.1839 million shares.
According to the latest equity disclosure data from the Hong Kong Stock Exchange on October 15, 2024, innovent bio (01801.HK) received a shareholding of 10.1839 million shares at an average price of HK$48.0257 per share from JPMorgan Chase & Co. on October 8, 2024, involving approximately HK$0.489 billion. After the shareholding, JPMorgan Chase & Co.'s latest holding of good warehouses is 102,360,912 shares, and the proportion of good warehouses held has increased from 5.65% to 6.25%.
Hong Kong Stocks Fall on Uncertainty in Further Stimulus; Pharma Firms Lead Decline
No Data
No Data